title: [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
abstract: There are many reports that octreotide acetate(SMS)is effective for terminally ill cancer patients with malignant bowel obstructions such as nausea, vomiting and abdominal distension. We retrospectively found that the clinical efficacy of SMS in 23 patients with these symptoms depended on the early terminal stage(about six months until death)or middle terminal stage(within one month until death). SMS was more effective to relieve abdominal distension(p=0. 01)and these bowel symptoms occurred among cancer patients in the early terminal stage rather than in the middle terminal stage(p<0. 001).
authors.affiliation: Dept. of Surgery, National Hospital Organization, Kumamoto Saishunsou Hospital.
authors.forename: Ryojin
authors.initials: R
authors.lastname: Uchino
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kusano
authors.forename: Norihisa
authors.initials: N
authors.lastname: Hanada
authors.forename: Chitoshi
authors.initials: C
authors.lastname: Ohara
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Okino
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamaguchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007415:Intestinal Obstruction / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D015282:Octreotide / Q000627:therapeutic use*; D012189:Retrospective Studies; D013727:Terminal Care
chemical_list: D005765:Gastrointestinal Agents; D015282:Octreotide